Randomized controlled trialHuman
Once-Weekly Semaglutide in Adults with Overweight or Obesity
The New England journal of medicine, 2021 Mar 18. Wilding JPH, Batterham RL, Calanna S and 12 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2021 Mar 18
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Semaglutide →glp1 muscle loss data →peptides for weight loss proven vs hype →peptides vs sarms →semaglutide vs tirzepatide vs retatrutide →
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultAnti-Obesity AgentsBody CompositionBody Mass IndexCholelithiasisDiarrheaDouble-Blind MethodFemaleGlucagon-Like Peptide 1Glucagon-Like PeptidesHealthy LifestyleHumans
Other papers on Semaglutide
Randomized controlled trial · 2025
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
Randomized controlled trial · 2023Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Randomized controlled trial · 2016Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page